Liquidia Technologies Inc

Liquidia Technologies Inc. is a biopharmaceutical company headquartered in Morrisville, North Carolina. With a workforce of 108 employees, the company generates approximately $50 million in annual revenue. Liquidia Corporation specializes in the development and commercialization of innovative products utilizing its proprietary PRINT® Technology. Their primary focus is on treating pulmonary hypertension, a serious condition affecting blood flow in the lungs. Liquidia's flagship product, YUTREPIA™ (treprostinil) inhalation powder, is approved for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). They are also actively developing L606, an investigational liposomal formulation of treprostinil, intended for twice-daily administration via a novel nebulizer. Liquidia's subsidiary, Liquidia PAH, plays a crucial role in the commercialization of pharmaceutical products designed to treat pulmonary diseases. This includes the availability of generic Treprostinil Injection, expanding treatment options for patients. For further information or inquiries, please visit Liquidia Technologies Inc.'s website at liquidia.com.